About the Journal

Download [This article belongs to Volume - 63, Issue - 09]

Abstract : Cancer is the second major reason of death worldwide. Chemotherapy treatment causes various adverse effects. Co-administration of immuno-modulatory agents with chemotherapy may result in better responses with fewer side effects. This work evaluated camel and goat milk (CM and GM) consuming pre and/ or post (neo-adjuvant and /or adjuvant) on the risks of cisplatin treatment in cancerous mice. Camel and goat milk nutritional and active composition were estimated. 20 mice kept healthy, 20 mice injected with cisplatin only and Ehrlich ascites carcinoma injection used to induce Ehrlich solid carcinoma in 120 mice. Cisplatin was injected once (3.5mg/kg mouse intra-peritoneal). CM or GM was orally (0.4ml /20g mouse) co-treated with cisplatin as neo-adjuvant and /or adjuvant. After 39 days mice were sacrificed, blood, tummor and bone marrow were separated to perform biochemical, genetic, tummor immunohistochemical, and histo-pathological studies. CM and GM were full of nutritional and immuno-modulatory components. Pre and/ or post CM or GM co-administration caused a significant (p≤0.05) improvement in hematological profile, antioxidant status, reversed the cisplatin-induced inflammation and elevated liver enzyme activities. CM or GM co-treatment with cisplatin resulted in a significant decreases (p≤0.05) in bone marrow tissues apoptosis, DNA damage and tumor cell proliferation. Also both milk enhanced the anti-tumor effects of cisplatin by a reduction of tumor size and weight. Microscopic examination of bone marrow tissues and tumor masses confirmed these results. Both milk modulated the risks of cisplatin treatment in cancerous mice without compromising its antitumor efficacy. Pre and post camel milk co-administration recorded the most significant improvements.